About Bliss Bio Health

Bliss Bio develops tumor-targeting biopharmaceuticals and antibody-drug conjugates (ADCs) to address unmet clinical needs in cancer treatment. The company focuses on creating differentiated biologic therapies through a combination of in-house research and strategic collaborations, aiming to improve patient outcomes in various tumor indications.

```xml <problem> Many cancer treatments lack specificity, leading to systemic toxicity and reduced efficacy. There remains a significant unmet need for targeted therapies that selectively eliminate tumor cells while sparing healthy tissue. </problem> <solution> BlissBio is a clinical-stage biotechnology company focused on developing innovative tumor-targeting antibody-drug conjugates (ADCs) and biopharmaceuticals for oncology. The company leverages its proprietary technology platforms and GMP-certified manufacturing facility to create differentiated biologic therapies. BlissBio's pipeline includes multiple ADCs in Phase I and Phase II clinical trials, targeting a variety of oncology indications. Through internal research and strategic collaborations, BlissBio aims to improve patient outcomes by delivering potent cytotoxic payloads directly to cancer cells, minimizing off-target effects. </solution> <features> - Proprietary ADC technology platforms for site-specific drug conjugation and optimized linker design - GMP-certified manufacturing facility for in-house production of antibodies and ADCs - Pipeline of tumor-targeting ADCs in Phase I and Phase II clinical trials - Focus on oncology indications with unmet clinical needs - Strategic collaborations to accelerate the development and commercialization of innovative biotherapeutics </features> <target_audience> The primary target audience includes patients with various types of cancer, as well as oncologists and other healthcare professionals involved in cancer treatment. </target_audience> ```

What does Bliss Bio Health do?

When was Bliss Bio Health founded?

Bliss Bio Health was founded in 2023.

Founded

2023

Employees

10 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Bliss Bio Health

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

blissbiopharma.com 700+

Founded 2023

Funding

No funding information available.

Team (10+)

No team information available.

Company Description

Problem

Many cancer treatments lack specificity, leading to systemic toxicity and reduced efficacy. There remains a significant unmet need for targeted therapies that selectively eliminate tumor cells while sparing healthy tissue.

Solution

BlissBio is a clinical-stage biotechnology company focused on developing innovative tumor-targeting antibody-drug conjugates (ADCs) and biopharmaceuticals for oncology. The company leverages its proprietary technology platforms and GMP-certified manufacturing facility to create differentiated biologic therapies. BlissBio's pipeline includes multiple ADCs in Phase I and Phase II clinical trials, targeting a variety of oncology indications. Through internal research and strategic collaborations, BlissBio aims to improve patient outcomes by delivering potent cytotoxic payloads directly to cancer cells, minimizing off-target effects.

Features

Proprietary ADC technology platforms for site-specific drug conjugation and optimized linker design

GMP-certified manufacturing facility for in-house production of antibodies and ADCs

Pipeline of tumor-targeting ADCs in Phase I and Phase II clinical trials

Focus on oncology indications with unmet clinical needs

Strategic collaborations to accelerate the development and commercialization of innovative biotherapeutics

Target Audience

The primary target audience includes patients with various types of cancer, as well as oncologists and other healthcare professionals involved in cancer treatment.